Challenges of treating mixed arterial-venous disease of lower extremities

Harding, Joel; Hedayati, Nasim

doi:10.23736/s0021-9509.21.11901-9

Cited by 2 publications

(1 citation statement)

References 64 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It is postulated that the coexistence of both venous and arterial diseases accounted for 26% of patients with lower extremity ulceration [ 21 ]. This kind of mixed leg ulcer pose a particular challenge in clinical practice, because they are recalcitrant due to the different underlying pathologies [ 22 ]. However, due to the multiple effects of pentoxifylline on both venous and arterial disease, the results of this study might introduce a new choice for mixed arterial-venous ulcers.…”

Section: Discussionmentioning

confidence: 99%

Efficacy and safety of pentoxifylline for chronic venous leg ulcers: study protocol for a multicenter randomized controlled trial in China (ESPECT study)

Gao

Liu

Qiu

et al. 2023

Trials

View full text Add to dashboard Cite

Background Venous leg ulcers (VLUs) are the most severe manifestation of chronic venous disease, with long healing time and a high recurrence rate. It imposes a heavy burden on patients, their families, and the health care system. Chronic inflammation triggered by sustained venous hypertension is now recognized as the hallmark of chronic venous disease. The anti-inflammatory effect of pentoxifylline may offer a promising avenue to treat VLUs. However, current evidence of pentoxifylline for VLUs is relatively small and of low quality. The aim of this study is to evaluate the efficacy and safety of pentoxifylline for VLUs in the Chinese population. Methods This is a randomized, double-blinded, double-dummy, multi-center, placebo-controlled clinical trial. A total of 240 patients will be randomized to receive pentoxifylline (400 mg, twice daily) or placebo for 24 weeks. All participants will receive diosmin treatment and standard care of VLUs and other comorbidities. The primary outcome is the difference in the wound healing rate within 12 weeks between pentoxifylline and placebo. Secondary outcomes include (1) percent wound size changes at 12 weeks, (2) the levels of TNF-α and IL-6, (3) venous clinical severity score and chronic venous insufficiency quality of life score, and (4) ulcer recurrence within 24 weeks. Discussion This study would evaluate the efficacy and safety of pentoxifylline for VLUs in the Chinese population. If confirmed, it wound offer another effective and safe therapeutic option for treatment of VLUs. Trial registration The trial was registered at the Chinese Clinical Trial Registry (No. ChiCTR-2100053053). Registered on 10 November, 2021, https://www.chictr.org.cn/showproj.aspx?proj=137010

show abstract

Section: Discussionmentioning

confidence: 99%